WO2001025437A3 - Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers - Google Patents

Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers Download PDF

Info

Publication number
WO2001025437A3
WO2001025437A3 PCT/US2000/027671 US0027671W WO0125437A3 WO 2001025437 A3 WO2001025437 A3 WO 2001025437A3 US 0027671 W US0027671 W US 0027671W WO 0125437 A3 WO0125437 A3 WO 0125437A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
nucleic acids
acids encoding
encoding same
factor polypeptides
Prior art date
Application number
PCT/US2000/027671
Other languages
English (en)
Other versions
WO2001025437A2 (fr
Inventor
Richard A Shimkets
Henri Lichenstein
John L Herrmann
Ferenc L Boldog
Stacey Minskoff
Michael Jeffers
Original Assignee
Curagen Corp
Richard A Shimkets
Henri Lichenstein
John L Herrmann
Ferenc L Boldog
Mi Stacey
Michael Jeffers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets, Henri Lichenstein, John L Herrmann, Ferenc L Boldog, Mi Stacey, Michael Jeffers filed Critical Curagen Corp
Priority to JP2001528589A priority Critical patent/JP2003511030A/ja
Priority to EP00968820A priority patent/EP1222279A2/fr
Priority to CA002386383A priority patent/CA2386383A1/fr
Priority to AU78680/00A priority patent/AU7868000A/en
Publication of WO2001025437A2 publication Critical patent/WO2001025437A2/fr
Publication of WO2001025437A3 publication Critical patent/WO2001025437A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux acides nucléiques codant pour des protéines et des polypeptides associés à une protéine-1 morphogénétique osseuse (BMF1) et à un facteur de croissance endothélial vasculaire E (VEGF-E) et un facteur de croissance d'origine plaquettaire (PDGF).
PCT/US2000/027671 1999-10-07 2000-10-06 Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers WO2001025437A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001528589A JP2003511030A (ja) 1999-10-07 2000-10-06 成長因子ポリペプチドおよび成長因子ポリペプチドをコードする核酸
EP00968820A EP1222279A2 (fr) 1999-10-07 2000-10-06 Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
CA002386383A CA2386383A1 (fr) 1999-10-07 2000-10-06 Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
AU78680/00A AU7868000A (en) 1999-10-07 2000-10-06 Growth factor polypeptides and nucleic acids encoding same

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US15808399P 1999-10-07 1999-10-07
US60/158,083 1999-10-07
US15923199P 1999-10-13 1999-10-13
US60/159,231 1999-10-13
US17448500P 2000-01-04 2000-01-04
US60/174,485 2000-01-04
US18670700P 2000-03-03 2000-03-03
US60/186,707 2000-03-03
US18825000P 2000-03-10 2000-03-10
US60/188,250 2000-03-10
US22387900P 2000-08-08 2000-08-08
US60/223,879 2000-08-08
US66278300A 2000-09-12 2000-09-12
US09/662,783 2000-09-12
US23408200P 2000-09-20 2000-09-20
US60/234,082 2000-09-20

Publications (2)

Publication Number Publication Date
WO2001025437A2 WO2001025437A2 (fr) 2001-04-12
WO2001025437A3 true WO2001025437A3 (fr) 2002-04-18

Family

ID=27575000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027671 WO2001025437A2 (fr) 1999-10-07 2000-10-06 Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers

Country Status (5)

Country Link
EP (1) EP1222279A2 (fr)
JP (1) JP2003511030A (fr)
AU (1) AU7868000A (fr)
CA (1) CA2386383A1 (fr)
WO (1) WO2001025437A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
WO2001089450A2 (fr) * 2000-05-19 2001-11-29 Eli Lilly And Company Traitement de pathologies musculosquelettiques par le polypeptide lp85 et des analogues de celui-ci
DK1355655T5 (da) * 2000-10-30 2007-08-13 Zymogenetics Inc Præparater og fremgangsmåder til forbedring af nyrefunktion
AU2002248201A1 (en) * 2000-11-16 2002-08-06 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
CN1303102C (zh) * 2002-11-13 2007-03-07 中国科学院上海生命科学研究院 利用人和鼠Rhor基因及其编码产物诊断和治疗秃发的方法
US8076061B2 (en) 2007-09-07 2011-12-13 Ascentgene, Inc. Method and composition for cancer diagnosis and treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047677A2 (fr) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologues de vegf et bmp1
WO2000027879A1 (fr) * 1998-11-10 2000-05-18 Ludwig Institute For Cancer Research Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations
WO2000034474A2 (fr) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance
WO2000066736A1 (fr) * 1999-05-03 2000-11-09 Zymogenetics, Inc. Homologue du facteur de croissance zvegf4
WO2001000878A2 (fr) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Nouveau membre de la famille des facteurs de croissance des cellules endotheliales vasculaires et son utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047677A2 (fr) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologues de vegf et bmp1
WO2000027879A1 (fr) * 1998-11-10 2000-05-18 Ludwig Institute For Cancer Research Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations
WO2000034474A2 (fr) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance
WO2000066736A1 (fr) * 1999-05-03 2000-11-09 Zymogenetics, Inc. Homologue du facteur de croissance zvegf4
WO2001000878A2 (fr) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Nouveau membre de la famille des facteurs de croissance des cellules endotheliales vasculaires et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 July 1997 (1997-07-01), ROBERT STRAUSBERG: "aa54c10.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824754 5'", XP002182497, retrieved from EBI Database accession no. AA488780 *

Also Published As

Publication number Publication date
WO2001025437A2 (fr) 2001-04-12
CA2386383A1 (fr) 2001-04-12
EP1222279A2 (fr) 2002-07-17
AU7868000A (en) 2001-05-10
JP2003511030A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
AU2002333623A1 (en) Antisense modulation of vascular endothelial growth factor receptor-1 expression
AU6515499A (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
PT814827E (pt) Factor de crescimento vascular endotelial-b
AU7368100A (en) Fibroblast growth factor polypeptide and nucleic acids encoding same
EP1283268A3 (fr) Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)
AU7714898A (en) Bone morphogenetic proteins and their use in bone growth
CA2097063A1 (fr) Compositions contenant un produit qui protege les tissus et un facteur de croissance, qui accelerent la cicatrisation des blessures
CA2258502A1 (fr) Facteur viii modifie
AU5439998A (en) Vascular endothelial growth factor
AU2002252631A1 (en) Vascular endothelial growth factor 2
AU3866097A (en) Naphtholactams and lactones as bone morphogenetic protein active agents
WO1998049300A3 (fr) Formes tronquees de proteines apparentees au facteur vegf
AU1478301A (en) Staphylococcus epidermidis nucleic acids and proteins
WO2002083850A8 (fr) Facteur 2 de croissance endotheliale vasculaire
AU5023300A (en) Vascular endothelial growth factor variants
AU6242098A (en) Endothelial pas domain protein
WO2000024412A3 (fr) Utilisation du gene ou de la proteine vegf-c ou vegf-d pour prevenir la restenose
WO2001025437A3 (fr) Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
ZA981339B (en) Transgenic animal with recombinant vascular endothelial growth factor B (vegf-b) dna and uses thereof
AU5026100A (en) Vascular endothelial growth factor dimers
DK0972520T3 (da) Frysetörret sammensætning af humant, knoglemorfogenetisk protein MP52
AU4409899A (en) Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
AU7846000A (en) Novel human lipase proteins, nucleic acids encoding them, and uses of both of these
AU1525499A (en) Ikap proteins, nucleic acids and methods
WO2002059618A3 (fr) Polypeptides de facteur de croissance et acides nucleiques codant pour ces polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2386383

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 78680/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 528589

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000968820

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000968820

Country of ref document: EP